179 related articles for article (PubMed ID: 38131168)
1. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
[TBL] [Abstract][Full Text] [Related]
3. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract][Full Text] [Related]
4. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
[TBL] [Abstract][Full Text] [Related]
5. A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice.
Cortez NE; Rodriguez Lanzi C; Hong BV; Xu J; Wang F; Chen S; Ramsey JJ; Pontifex MG; Müller M; Vauzour D; Vahmani P; Hwang CI; Matsukuma K; Mackenzie GG
Cancer Res Commun; 2022 Sep; 2(9):951-965. PubMed ID: 36382086
[TBL] [Abstract][Full Text] [Related]
6. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.
Husain K; Centeno BA; Chen DT; Hingorani SR; Sebti SM; Malafa MP
Cancer Prev Res (Phila); 2013 Oct; 6(10):1074-83. PubMed ID: 23963802
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
9. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract][Full Text] [Related]
10. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
[TBL] [Abstract][Full Text] [Related]
11. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
12. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
13. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.
Carapuça EF; Gemenetzidis E; Feig C; Bapiro TE; Williams MD; Wilson AS; Delvecchio FR; Arumugam P; Grose RP; Lemoine NR; Richards FM; Kocher HM
J Pathol; 2016 Jul; 239(3):286-96. PubMed ID: 27061193
[TBL] [Abstract][Full Text] [Related]
14. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
Plassmeier L; Knoop R; Waldmann J; Kesselring R; Buchholz M; Fichtner-Feigl S; Bartsch DK; Fendrich V
Langenbecks Arch Surg; 2013 Oct; 398(7):989-96. PubMed ID: 23989613
[TBL] [Abstract][Full Text] [Related]
15. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.
Ferro R; Adamska A; Lattanzio R; Mavrommati I; Edling CE; Arifin SA; Fyffe CA; Sala G; Sacchetto L; Chiorino G; De Laurenzi V; Piantelli M; Sansom OJ; Maffucci T; Falasca M
Oncogene; 2018 Dec; 37(49):6368-6382. PubMed ID: 30061636
[TBL] [Abstract][Full Text] [Related]
16. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
Wolfe AR; Robb R; Hegazi A; Abushahin L; Yang L; Shyu DL; Trevino JG; Cruz-Monserrate Z; Jacob JR; Palanichamy K; Chakravarti A; Williams TM
Clin Cancer Res; 2021 Jan; 27(2):554-565. PubMed ID: 33087331
[TBL] [Abstract][Full Text] [Related]
17. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan.
Rodriguez Lanzi C; Wei R; Luo D; Mackenzie GG
Neoplasia; 2022 Feb; 24(2):133-144. PubMed ID: 34968866
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study.
de Castro Silva I; Bianchi A; Deshpande NU; Sharma P; Mehra S; Garrido VT; Saigh SJ; England J; Hosein PJ; Kwon D; Merchant NB; Datta J
Elife; 2022 Sep; 11():. PubMed ID: 36107485
[TBL] [Abstract][Full Text] [Related]
19. Modulation of Cancer-Associated Fibrotic Stroma by An Integrin α
Turaga RC; Sharma M; Mishra F; Krasinskas A; Yuan Y; Yang JJ; Wang S; Liu C; Li S; Liu ZR
Cell Mol Gastroenterol Hepatol; 2021; 11(1):161-179. PubMed ID: 32810598
[TBL] [Abstract][Full Text] [Related]
20. A Ketogenic Diet in Combination with Gemcitabine Mitigates Pancreatic Cancer-Associated Cachexia in Male and Female KPC Mice.
Cortez NE; Pathak S; Rodriguez Lanzi C; Hong BV; Crone R; Sule R; Wang F; Chen S; Gomes AV; Baar K; Mackenzie GG
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]